Bevacizumab
Monoclonal antibody
Biosimilars tracked: Alymsys (bevacizumab-maly), BP-102, Jobevne (bevacizumab-nwgd), Vegzelma (bevacizumab-adcd), Zirabev (bevacizumab-bvzr), bevacizumab-awwb
Evidence outlook
Approved: Non-Small Cell Lung Cancer, Recurrent Glioblastoma, Colorectal Cancer, Hepatocellular Carcinoma, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer, Metastatic Colorectal Cancer
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (2)
- AVASTIN (bevacizumab for injection) is indicated for: • Metastatic Colorectal Cancer (mCRC) - Avastin in combination with fluoropyrimidine-based chemotherapy is indicated for first-line treatment of patients with metastatic carcinoma of the colon or rectum. - Consideration should be given to current standard of care guidelines for colorectal cancer. - See Drug-Drug Interactions for further information on the use of Avastin in combination with irinotecan. - Please refer to the Product Monographs for irinotecan, 5-fluorouracil and leucovorin for additional information on these products, and...
- Bevacizumab in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. Bevacizumab in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status. Bevacizumab in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines...
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT00806923 NCT00806923 · Non-Squamous Non-Small Cell Lung Cancer This is a large, randomized, placebo-controlled trial with a clinical primary endpoint (progression-free survival). Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Registry: NCT00806923 | 3 | Progression-free survival (Event driven) 2011-02 | Progression-free survival: HR 0.75 (95% CI 0.64-0.87; P=0.0003) for bevacizumab 7.5 mg/kg + cisplatin/gemcitabine vs placebo + cisplatin/gemcitabine, and HR 0.85 (95% CI 0.73-1.00; P=0.0456) for bevacizumab 15 mg/kg vs placebo | Partial signal | link ↗ |
View 1 more trial
NCT00021060 NCT00021060 · Non-Small Cell Lung Cancer This was a large randomized trial with a chemotherapy-alone control arm, and its primary endpoint, overall survival, was significantly longer with bevacizumab (hazard ratio 0.79, P=0.003). Survival is an objective endpoint, but the trial was open-label, so neither patients nor doctors were blinded to treatment. Caveat: this result is taken from the peer-reviewed paper (Sandler et al., N Engl J Med 2006, PMID 17167137); the ClinicalTrials.gov record has no posted results. Registry: NCT00021060 | 2/3 | Survival (Up to 5 years); Grade 4 or 5 toxicities assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 (Up to 5 years) 2006-09 | Overall survival, paclitaxel-carboplatin plus bevacizumab (n=434) vs paclitaxel-carboplatin alone (n=444): median 12.3 vs 10.3 months, hazard ratio for death 0.79, P = 0.003 (Sandler et al., NEJM 2006). | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (300)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (66)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (1366)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (245)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (370)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (73)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (142)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (133)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (50)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (44)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (15)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (3)
What this study did
What this study did
What this study did
Appears in other studies (87)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 3 (33)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (4)
What this study did
What this study did
What this study did
What this study did
Phase 2 (38)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (1)
What this study did
Early phase / not applicable (4)
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other VEGF-A drugs
Aflibercept, aflibercept-abzv (Enzeevu), aflibercept-ayyh (Pavblu), aflibercept-boav (Eydenzelt), aflibercept-jbvf (Yesafili) and 33 more. Compare all 39 VEGF-A drugs
This mechanism is crowded: 38 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Cervical Cancer: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Bevacizumab: this drug | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | not yet graded | No reviewed efficacy summary in this indication | |
| Aflibercept (Eylea) | Approved(overall) | Protein / enzyme therapeutic | VEGF-A, VEGF-A / VEGF-B / Placental Growth Factor (PlGF) | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Aflibercept-Abzv (Enzeevu) | Approved(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Aflibercept-Ayyh (Pavblu) | Approved(overall) | Protein / enzyme therapeutic | VEGF-A | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Aflibercept-Boav (Eydenzelt) | Approved(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Aflibercept-Jbvf (Yesafili) | Approved(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Aflibercept-Mrbb (Ahzantive) | Approved(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Aflibercept-Yszy (Opuviz) | Approved(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Brolucizumab-Dbll | Approved(overall) | Antibody fragment | VEGF-A | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Jobevne (bevacizumab-Nwgd) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Reliable signal | No reviewed efficacy summary in this indication | |
| Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex) | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Ranibizumab (Lucentis) | Approved(overall) | Antibody fragment | VEGF-A | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Ranibizumab-Eqrn (Cimerli) | Approved(overall) | Monoclonal antibody | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Ranibizumab-Hkdz (Ranluspec) | Approved(overall) | Monoclonal antibody | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Ranibizumab-Leyk (Nufymco) | Approved(overall) | Monoclonal antibody | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Ranibizumab-Nuna (Byooviz) | Approved(overall) | Monoclonal antibody | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Tisotumab Vedotin Humax-Tf-Adc (Tivdak) | Approved | Antibody–drug conjugate | Tissue Factor (TF) | Partial signal | NCT04697628: Overall Survival (From randomization to date of death due to any cause or censoring date, whichever occurred first (maximum up to 25 months)): Tisotumab Vedotin 11.5 Months (95% CI 9.8 to 14.9) | Chemotherapy 9.5 Months (95% CI 7.9 to 10.7) NCT03438396: Percentage of Participants With Confirmed Objective Response (OR) as Assessed by the Independent Review Committee (IRC) (From Day 1 through IRC verified disease progression, initiation of new anticancer therapy, study withdrawal, or death, whichever occurred first (approximately 20 months)): Tisotumab Vedotin 23.8 Percentage of Participants (95% CI 15.9 to 33.3) | |
| Vegzelma (bevacizumab-Adcd) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Zirabev (bevacizumab-Bvzr) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| BAT5906 | Phase 3(overall) | Monoclonal antibody | VEGF-A | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Cadonilimab | Phase 3 | Multispecific antibody | PD-1×CTLA-4 | not yet graded | No reviewed efficacy summary in this indication | |
| CKD-701 (Lucenbies) | Phase 3(overall) | Monoclonal antibody | VEGF-A | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Enlonstobart | Phase 3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Famitinib | Phase 3 | Small molecule | c-Kit, VEGFR2 (KDR), PDGFRbeta, VEGFR3, FLT1, FLT3 | not yet graded | No reviewed efficacy summary in this indication | |
| HLX04-O | Phase 3(overall) | Monoclonal antibody | VEGF-A | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Notiretatug Rezetecan | Phase 3 | Antibody–drug conjugate | Nectin-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Ranibizumab (Ximluci) | Phase 3(overall) | Monoclonal antibody | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Sacituzumab Tirumotecan | Phase 3 | Antibody–drug conjugate | TROP2 | not yet graded | No reviewed efficacy summary in this indication | |
| Surabgene Lomparvovec | Phase 3(overall) | Gene therapy / editing | VEGF-A | Weak signal(overall) | No reviewed efficacy summary in this indication | |
| Sutantatug Envedotin | Phase 3 | Antibody–drug conjugate | Nectin-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Tarcocimab Tedromer | Phase 3(overall) | Monoclonal antibody | VEGF-A | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Volrustomig | Phase 3 | Multispecific antibody | PD-1 x CTLA-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Camrelizumab | Phase 2/3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| MW02 | Phase 2/3(overall) | Monoclonal antibody | VEGF-A | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Balstilimab | Phase 2 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| ALE.P02 | Phase 1/2(overall) | Antibody–drug conjugate | Claudin-1 (CLDN1) | not yet graded | No reviewed efficacy summary in this indication | |
| GI-101A | Phase 1/2 | Protein / enzyme therapeutic | CTLA-4 / IL-2Rβγ | not yet graded | No reviewed efficacy summary in this indication | |
| Ranibizumab (Rimmyrah) | Phase 1(overall) | Monoclonal antibody | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Aflibercept (Afiveg) | —(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Aflibercept (Eyluxvi) | —(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Aflibercept (Mynzepli) | —(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Aflibercept (Vgenfli) | —(overall) | Protein / enzyme therapeutic | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Ranibizumab (Ranivisio) | —(overall) | Monoclonal antibody | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Ranibizumab (Rexatilux) | —(overall) | Monoclonal antibody | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Telbermin | Discontinued | Protein / enzyme therapeutic | VEGF-A | not yet graded(overall) | No reviewed efficacy summary in this indication |
Compare side by side
4 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(458 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Bevacizumab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.